nach oben

Erschienen in:

01.02.2012 | Original article

Effect of glycosylation on biodistribution of radiolabeled glucagon-like peptide 1

verfasst von: Ayahisa Watanabe, Ken-ichi Nishijima, Songji Zhao, Yoshikazu Tanaka, Takeshi Itoh, Hiroshi Takemoto, Nagara Tamaki, Yuji Kuge

Erschienen in: Annals of Nuclear Medicine | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Objective

Glycosylation is generally applicable as a strategy for increasing the activity of bioactive proteins. In this study, we examined the effect of glycosylation on biodistribution of radiolabeled glucagon-like peptide 1 (GLP-1) as a bioactive peptide for type 2 diabetes.

Methods

Noninvasive imaging studies were performed using a gamma camera after the intravenous administration of ¹²³I-GLP-1 or ¹²³I-α2, 6-sialyl N-acetyllactosamine (glycosylated) GLP-1 in rats. In ex vivo biodistribution studies using ¹²⁵I-GLP-1 or ¹²⁵I-glycosylated GLP-1, organ samples were measured for radioactivity. Plasma samples were added to 15% trichloroacetic acid (TCA) to obtain TCA-insoluble and TCA-soluble fractions. The radioactivity in the TCA-insoluble and TCA-soluble fractions was measured.

Results

In the noninvasive imaging studies, a relatively high accumulation level of ¹²³I-GLP-1 was found in the liver, which is the major organ to eliminate exogenous GLP-1. The area under the time-activity curve (AUC) of ¹²³I-glycosylated GLP-1 in the liver was significantly lower (89%) than that of ¹²³I-GLP-1. These results were consistent with those of ex vivo biodistribution studies using ¹²⁵I-labeled peptides. The AUC of ¹²⁵I-glycosylated GLP-1 in the TCA-insoluble fraction was significantly higher (1.7-fold) than that of GLP-1.

Conclusions

This study demonstrated that glycosylation significantly decreased the distribution of radiolabeled GLP-1 into the liver and increased the concentration of radiolabeled GLP-1 in plasma. These results suggested that glycosylation is a useful strategy for decreasing the distribution into the liver of bioactive peptides as desirable pharmaceuticals.

Deacon CF. Therapeutic strategies based on glucagon-like peptide 1. Diabetes. 2004;53:2181–9.PubMedCrossRef

Arulmozhi DK, Portha B. GLP-1 based therapy for type 2 diabetes. Eur J Pharm Sci. 2006;28:96–108.PubMedCrossRef

Holst JJ, Ørskov C. The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism. Diabetes. 2004;53:S197–204.PubMedCrossRef

Holst JJ, Deacon CF, Vilsbøll T, Krarup T, Madsbad S. Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends Mol Med. 2008;14:161–8.PubMedCrossRef

Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev. 1999;20:876–913.PubMedCrossRef

Meier JJ, Nauck MA. Glucagon-like peptide 1 (GLP-1) in biology and pathology. Diabetes Metab Res Rev. 2005;21:91–117.PubMedCrossRef

Nauck MA, Meier JJ. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul Pept. 2005;128:135–48.PubMedCrossRef

Simonsen L, Holst JJ, Deacon CF. Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs. Diabetologia. 2006;49:706–12.PubMedCrossRef

Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol. 1996;271:E458–64.PubMed

10.

Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab. 1995;80:952–7.PubMedCrossRef

11.

Kieffer TJ, McIntosh CHS, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. 1995;136:3585–96.PubMedCrossRef

12.

Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7–36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993;214:829–35.PubMedCrossRef

13.

Hupe-Sodmann K, McGregor GP, Bridenbaugh R, Göke R, Göke B, Thole H, et al. Characterization of the processing by human neutral endopeptidase 24.11 of GLP-1 (7–36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept. 1995;58:149–56.PubMedCrossRef

14.

Hupe-Sodmann K, Göke R, Göke B, Thole HH, Zimmermann B, Voigt K, et al. Endoproteolysis of glucagon-like peptide (GLP)-1 (7–36) amide by ectopeptidases in RINm5F cells. Peptides. 1997;18:625–32.PubMedCrossRef

15.

Plamboeck A, Holst JJ, Carr RD, Deacon CF. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia. 2005;48:1882–90.PubMedCrossRef

16.

O’Harte FP, Mooney MH, Lawlor A, Flatt PR. N-terminally modified glucagon-like peptide-1 (7–36) amide exhibits resistance to enzymatic degradation while maintaining its antihyperglycaemic activity in vivo. Biochim Biophys Acta. 2000;1474:13–22.PubMedCrossRef

17.

Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia. 1998;41:271–8.PubMedCrossRef

18.

Chae SY, Chun YG, Lee S, Jin CH, Lee ES, Lee KC, et al. Pharmacokinetic and pharmacodynamic evaluation of site-specific PEGylated glucagon-like peptide-1 analogs as flexible postprandial-glucose controllers. J Pharm Sci. 2009;98:1556–67.PubMedCrossRef

19.

Lee SH, Lee S, Youn YS, Na DH, Chae SY, Byun Y, et al. Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. Bioconj Chem. 2005;16:377–82.CrossRef

20.

Göke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, et al. Exendin-4 is a high potency agonist and truncated exendin-(9–39)-amide an antagonist at the glucagon-like peptide 1-(7–36)-amide receptor of insulin-secreting beta-cells. J Biol Chem. 1993;268:19650–5.PubMed

21.

Thum A, Hupe-Sodmann K, Göke R, Voigt K, Göke B, McGregor GP. Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4. Exp Clin Endocrinol Diabetes. 2002;110:113–8.PubMedCrossRef

22.

Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, et al. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes. 1999;48:1026–34.PubMedCrossRef

23.

Sato M, Furuike T, Sadamoto R, Fujitani N, Nakahara T, Niikura K, et al. Glycoinsulins: dendritic sialyloligosaccharide-displaying insulins showing a prolonged blood-sugar-lowering activity. J Am Chem Soc. 2004;126:14013–22.PubMedCrossRef

24.

Sinclair AM, Elliott S. Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. J Pharm Sci. 2005;94:1626–35.PubMedCrossRef

25.

Elliott S, Lorenzini T, Asher S, Aoki K, Brankow D, Buck L, et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol. 2003;21:414–21.PubMedCrossRef

26.

Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol. 1999;10:2392–5.PubMed

27.

Ueda T, Tomita K, Notsu Y, Ito T, Fumoto M, Takakura T, et al. Chemoenzymatic synthesis of glycosylated glucagon-like peptide 1: effect of glycosylation on proteolytic resistance and in vivo blood glucose-lowering activity. J Am Chem Soc. 2009;131:6237–45.PubMedCrossRef

28.

Hunter R. Standardization of the chloramine-T method of protein iodination. Proc Soc Exp Biol Med. 1970;133:989–92.PubMed

29.

Webster R, Taberner J, Edgington A, Guhan S, Varghese J, Feeney H, et al. Role of sialylation in determining the pharmacokinetics of neutrophil inhibitory factor (NIF) in the Fischer 344 rat. Xenobiotica. 1999;29:1141–55.PubMedCrossRef

30.

Gabizon A, Papahadjopoulos D. The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim Biophys Acta. 1992;10:94–100.

31.

Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept. 1999;85:9–24.PubMedCrossRef

32.

Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372:1240–50.PubMedCrossRef

33.

Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10:1093–5.PubMedCrossRef

34.

Melis M, Vegt E, Konijnenberg MW, de Visser M, Bijster M, Vermeij M, et al. Nephrotoxicity in mice after repeated imaging using ¹¹¹In-labeled peptides. J Nucl Med. 2010;51:973–7.PubMedCrossRef

Titel: Effect of glycosylation on biodistribution of radiolabeled glucagon-like peptide 1
verfasst von: Ayahisa Watanabe
Ken-ichi Nishijima
Songji Zhao
Yoshikazu Tanaka
Takeshi Itoh
Hiroshi Takemoto
Nagara Tamaki
Yuji Kuge
Publikationsdatum: 01.02.2012
Verlag: Springer Japan
Erschienen in: Annals of Nuclear Medicine / Ausgabe 2/2012
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-011-0558-z

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

Use of an oral effervescent agent in the evaluation of gastric 67Ga uptake

Erratum to: Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT

PET scanning in plastic and reconstructive surgery

Usefulness of 18F-FDG uptake with clinicopathologic and immunohistochemical prognostic factors in breast cancer

The agreement of left ventricular function parameters between 99mTc-tetrofosmin gated myocardial SPECT and gated myocardial MRI

Correlated regions of cerebral blood flow with clinical parameters in Parkinson’s disease; comparison using ‘Anatomy’ and ‘Talairach Daemon’ software